Literature DB >> 20569705

Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data.

Naoki Sato1, Katsuya Kajimoto, Kuniya Asai, Masayuki Mizuno, Yuichiro Minami, Michitaka Nagashima, Koji Murai, Ryo Muanakata, Dai Yumino, Tomomi Meguro, Masatoshi Kawana, Jun Nejima, Toshihiko Satoh, Kyoichi Mizuno, Keiji Tanaka, Hiroshi Kasanuki, Teruo Takano.   

Abstract

Acute heart failure syndromes (AHFS) are likely to increase in the future, and the high readmission rate of patients with AHFS is an important issue in Western countries. However, there are very few published epidemiological studies on AHFS in the Asia Pacific region. Because AHFS are heterogeneous, the characteristics, clinical profile, and management of AHFS should be clarified in an epidemiological study. The acute decompensated heart failure syndromes (ATTEND) registry is a prospective, observational, multicenter cohort study being performed in Japan and is the first epidemiological study of AHFS in the Asia Pacific region. This study is designed to investigate several aspects of AHFS as follows: (1) the registry allows patient-based data collection for precise evaluation of patient characteristics and short-term outcomes, including the readmission rate; (2) confirmation of clinical assessments can be performed, and new clinical assessments can be created; and (3) feedback allows the modification of guidelines for clinical management. The present report describes the clinical characteristics of patients with AHFS in Japan based on the preliminary data collected in this study, and the similarities and differences in characteristics of these patients compared with those in Western countries. Although most of the patient characteristics did not differ from those reported in Western studies, there are some unique findings in this study, including a high rate of treatment with carperitide (69.4%) and angiotensin II receptor blockers (53.9%) at discharge and a longer hospital stay (median 21 days). The ATTEND registry is designed to provide valuable information to clarify the characteristics of patients with AHFS to improve their management. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20569705     DOI: 10.1016/j.ahj.2010.03.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  64 in total

1.  Length of hospital stay and its impact on subsequent early readmission in patients with acute heart failure: a report from the WET-HF Registry.

Authors:  Hidenori Moriyama; Takashi Kohno; Shun Kohsaka; Yasuyuki Shiraishi; Ryoma Fukuoka; Yuji Nagatomo; Ayumi Goda; Atsushi Mizuno; Keiichi Fukuda; Tsutomu Yoshikawa
Journal:  Heart Vessels       Date:  2019-05-27       Impact factor: 2.037

Review 2.  Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Authors:  Massimo Volpe; Speranza Rubattu; John Burnett
Journal:  Eur Heart J       Date:  2013-11-13       Impact factor: 29.983

3.  Weekend versus weekday hospital admission and outcomes during hospitalization for patients due to worsening heart failure: a report from Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD).

Authors:  Sanae Hamaguchi; Shintaro Kinugawa; Miyuki Tsuchihashi-Makaya; Daisuke Goto; Hiroyuki Tsutsui
Journal:  Heart Vessels       Date:  2013-05-08       Impact factor: 2.037

4.  Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses.

Authors:  Masataka Ogiso; Toshiaki Isogai; Yuta Okabe; Kansuke Ito; Masaki Tsuji; Hiroyuki Tanaka
Journal:  Heart Vessels       Date:  2017-02-20       Impact factor: 2.037

Review 5.  Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy.

Authors:  Jozine M ter Maaten; Mattia A E Valente; Kevin Damman; Hans L Hillege; Gerjan Navis; Adriaan A Voors
Journal:  Nat Rev Cardiol       Date:  2015-01-06       Impact factor: 32.419

6.  Associations of anemia and renal dysfunction with outcomes among patients hospitalized for acute decompensated heart failure with preserved or reduced ejection fraction.

Authors:  Katsuya Kajimoto; Naoki Sato; Takehiko Keida; Yasushi Sakata; Teruo Takano
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-02       Impact factor: 8.237

7.  Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.

Authors:  Ryuichi Matsukawa; Toru Kubota; Masanori Okabe; Yusuke Yamamoto; Hiroshi Meno
Journal:  Heart Vessels       Date:  2017-08-16       Impact factor: 2.037

8.  Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.

Authors:  Mihai Gheorghiade; Muthiah Vaduganathan; Stephen J Greene; Robert J Mentz; Kirkwood F Adams; Stefan D Anker; Malcolm Arnold; Fabio Baschiera; John G F Cleland; Gadi Cotter; Gregg C Fonarow; Christopher Giordano; Marco Metra; Frank Misselwitz; Eva Mühlhofer; Savina Nodari; W Frank Peacock; Burkert M Pieske; Hani N Sabbah; Naoki Sato; Monica R Shah; Norman L Stockbridge; John R Teerlink; Dirk J van Veldhuisen; Andrew Zalewski; Faiez Zannad; Javed Butler
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

9.  Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study.

Authors:  Yoshitaka Okuhara; Shinichi Hirotani; Tomotaka Ando; Koichi Nishimura; Yoshiyuki Orihara; Kazuo Komamura; Yoshiro Naito; Toshiaki Mano; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-07-28       Impact factor: 2.037

Review 10.  Novel pharmacologic therapies in development for acute decompensated heart failure.

Authors:  Justin A Ezekowitz
Journal:  Curr Cardiol Rep       Date:  2013-02       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.